Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 15;11(3):330-347.
eCollection 2021.

Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension

Affiliations
Review

Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension

Amanda Lloji et al. Am J Cardiovasc Dis. .

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a form of pulmonary hypertension (PH) caused by thromboembolic disease with the secondary remodeling of the pulmonary vessels. The primary treatment of CTEPH is pulmonary thromboendarterectomy (PTE). However, some patients are not candidates for PTE because of surgically inaccessible thrombi or high operative risk and can be candidates for balloon pulmonary angioplasty (BPA), an emerging, lower risk treatment. This review discusses the patient selection, the technique, and comprehensive review of reported outcomes following BPA. BPA techniques have improved over the years, and so has its safety profile. Recent data show that after several sessions of BPA, patients who were not eligible for PTE had improvement in their hemodynamic profile, functional capacity, and 6-minute walk distance. Studies have shown that compared to riociguat, BPA has shown significant improvement in the functional capacity and hemodynamic measurements. Reperfusion pulmonary edema is a common complication after PTE and BPA, which may be due to vessel injury rather than pulmonary extravasation. Rates of complications have decreased especially after the use of optical coherence tomography, which helps in proper sizing of the balloons. Patients with CTEPH who are ineligible for PTE should be evaluated for BPA. In addition to medical therapy, BPA has shown promising clinical and hemodynamic outcomes in patients with CTEPH.

Keywords: Chronic thromboembolic pulmonary hypertension; balloon pulmonary angioplasty; pulmonary hypertension; pulmonary thromboendarterectomy.

PubMed Disclaimer

Conflict of interest statement

None.

References

    1. Lang IM, Dorfmuller P, Vonk Noordegraaf A. The pathobiology of chronic thromboembolic pulmonary hypertension. Ann Am Thorac Soc. 2016;13(Suppl 3):S215–221. - PubMed
    1. Lang IM, Madani M. Update on chronic thromboembolic pulmonary hypertension. Circulation. 2014;130:508–518. - PubMed
    1. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(Suppl):D34–41. - PubMed
    1. Yandrapalli S, Tariq S, Kumar J, Aronow WS, Malekan R, Frishman WH, Lanier GM. Chronic thromboembolic pulmonary hypertension: epidemiology, diagnosis, and management. Cardiol Rev. 2018;26:62–72. - PubMed
    1. Barco S, Russo M, Vicaut E, Becattini C, Bertoletti L, Beyer-Westendorf J, Bouvaist H, Couturaud F, Danays T, Dellas C, Duerschmied D, Empen K, Ferrari E, Galie N, Jimenez D, Klok FA, Kostrubiec M, Kozak M, Kupatt C, Lang IM, Lankeit M, Meneveau N, Palazzini M, Pruszczyk P, Rugolotto M, Salvi A, Sanchez O, Schellong S, Sobkowicz B, Meyer G, Konstantinides SV. Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the pulmonary embolism thrombolysis (PEITHO) trial. Clin Res Cardiol. 2019;108:772–778. - PMC - PubMed

LinkOut - more resources